Can antipsychotic treatment contribute to drug addiction in schizophrenia?

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 52, Issue , 2014, Pages 9-16

  Samaha, Anne Noël ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Dopamine supersensitivity; Dual diagnosis; Reward; Schizophrenia; Substance abuse; Typical atypical antipsychotic medication

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; NEUROLEPTIC AGENT;

ARTICLE; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINERGIC TRANSMISSION; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFECT; DRUG EXPOSURE; DRUG RESPONSE; HUMAN; LONG TERM EXPOSURE; MOTIVATION; NERVE CELL PLASTICITY; PREVALENCE; PSYCHOMOTOR ACTIVITY; REWARD; SCHIZOPHRENIA; SUPERSENSITIVITY; METABOLISM; SUBSTANCE-RELATED DISORDERS;

ANTIPSYCHOTIC AGENTS; DOPAMINE; HUMANS; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS;

EID: 84899653015     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.06.008     Document Type: Article

References (122)

1. Abramowski D., Rigo M., Duc D., Hoyer D., Staufenbiel M. Localization of the 5-hydroxytryptamine2C receptor protein in human and rat brain using specific antisera. Neuropharmacology 1995, 34:1635-1645.
2. Arroyo M., Markou A., Robbins T.W., Everitt B.J. Acquisition, maintenance and reinstatement of intravenous cocaine self-administration under a second-order schedule of reinforcement in rats: effects of conditioned cues and continuous access to cocaine. Psychopharmacology (Berl) 1998, 140:331-344.
3. Ase A.R., Amdiss F., Hebert C., Huang N., van Gelder N.M., Reader T.A. Effects of antipsychotic drugs on dopamine and serotonin contents and metabolites, dopamine and serotonin transporters, and serotonin1A receptors. J Neural Transm 1999, 106:75-105.
4. Asper H., Baggiolini M., Burki H.R., Lauener H., Ruch W., Stille G. Tolerance phenomena with neuroleptics catalepsy, apomorphine stereotypies and striatal dopamine metabolism in the rat after single and repeated administration of loxapine and haloperidol. Eur J Pharmacol 1973, 22:287-294.
5. Baigent M., Holme G., Hafner R.J. Self reports of the interaction between substance abuse and schizophrenia. Aust N Z J Psychiatry 1995, 29:69-74.
6. Baron J.C., Martinot J.L., Cambon H., Boulenger J.P., Poirier M.F., Caillard V., et al. Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology (Berl) 1989, 99:463-472.
7. Bedard A.M., Maheux J., Levesque D., Samaha A.N. Continuous, but not intermittent, antipsychotic drug delivery intensifies the pursuit of reward cues. Neuropsychopharmacology 2011, 36:1248-1259.
8. Bedard A.M., Maheux J., Levesque D., Samaha A.N. Prior Haloperidol, but not Olanzapine, Exposure Augments the Pursuit of Reward Cues: Implications for Substance Abuse in Schizophrenia. Schizophr Bull 2012, 39:692-702.
9. Bezchlibnyk-Butler K.Z., Jeffries J.J. Clinical Handbook of Psychotropic Drugs 1999, Hogrefe & Huber Publishers, Toronto.
10. Bouthenet M.L., Martres M.P., Sales N., Schwartz J.C. A detailed mapping of dopamine D-2 receptors in rat central nervous system by autoradiography with [125I]iodosulpride. Neuroscience 1987, 20:117-155.
11. Burt D.R., Creese I., Snyder S.H. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 1977, 196:326-328.
12. Carter B.L., Lam C.Y., Robinson J.D., Paris M.M., Waters A.J., Wetter D.W., et al. Generalized craving, self-report of arousal, and cue reactivity after brief abstinence. Nicotine Tob Res 2009, 11:823-826.
13. Chambers R.A., Krystal J.H., Self D.W. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry 2001, 50:71-83.
14. Cheng Y.F., Paalzow L.K. Linear pharmacokinetics of haloperidol in the rat. Biopharm Drug Dispos 1992, 13:69-76.
15. Chesi A.J., Feasey-Truger K.J., Alzheimer C., ten Bruggencate G. Dopamine autoreceptor sensitivity is unchanged in rat nucleus accumbens after chronic haloperidol treatment: an in vivo and in vitro voltammetric study. Eur J Neurosci 1995, 7:2450-2457.
16. Chouinard G., Jones B.D. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry 1980, 137:16-21.
17. Chouinard G., Jones B.D., Annable L. Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry 1978, 135:1409-1410.
18. Clemett D.A., Punhani T., Duxon M.S., Blackburn T.P., Fone K.C. Immunohistochemical localisation of the 5-HT2C receptor protein in the rat CNS. Neuropharmacology 2000, 39:123-132.
19. Clow A., Jenner P., Marsden C.D. Changes in dopamine-mediated behaviour during one year's neuroleptic administration. Eur J Pharmacol 1979, 57:365-375.
20. Cousijn J., Goudriaan A.E., Ridderinkhof K.R., van den Brink W., Veltman D.J., Wiers R.W. Neural responses associated with cue-reactivity in frequent cannabis users. Addict Biol 2012, 18(3):570-580.
21. Creese I., Snyder S.H. Chronic neuroleptic treatment and dopamine receptor regulation. Adv Biochem Psychopharmacol 1980, 24:89-94.
22. Dalack G.W., Healy D.J., Meador-Woodruff J.H. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatry 1998, 155:1490-1501.
23. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991, 148:1474-1486.
24. De Deurwaerdere P., Navailles S., Berg K.A., Clarke W.P., Spampinato U. Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J Neurosci 2004, 24:3235-3241.
25. de Wit H., Stewart J. Reinstatement of cocaine-reinforced responding in the rat. Psychopharmacology (Berl) 1981, 75:134-143.
26. DeQuardo J.R., Carpenter C.F., Tandon R. Patterns of substance abuse in schizophrenia: nature and significance. J Psychiatr Res 1994, 28:267-275.
27. Dixon L., Haas G., Weiden P.J., Sweeney J., Frances A.J. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psychiatry 1991, 148:224-230.
28. Drake R.E., Osher F.C., Noordsy D.L., Hurlbut S.C., Teague G.B., Beaudett M.S. Diagnosis of alcohol use disorders in schizophrenia. Schizophr Bull 1990, 16:57-67.
29. Duka T., Townshend J.M. The priming effect of alcohol pre-load on attentional bias to alcohol-related stimuli. Psychopharmacology (Berl) 2004, 176:353-361.
30. Egerton A., Ahmad R., Hirani E., Grasby P.M. Modulation of striatal dopamine release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the rat. Psychopharmacology (Berl) 2008, 200:487-496.
31. Ericson H., Radesater A.C., Servin E., Magnusson O., Mohringe B. Effects of intermittent and continuous subchronic administration of raclopride on motor activity, dopamine turnover and receptor occupancy in the rat. Pharmacol Toxicol 1996, 79:277-286.
32. Everitt B.J., Robbins T.W. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 2005, 8:1481-1489.
33. Ezrin-Waters C., Seeman P. L-DOPA reversal of hyperdopaminergic behaviour. Life Sci 1978, 22:1027-1032.
34. Farde L., Nordstrom A.L., Wiesel F.A., Pauli S., Halldin C., Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992, 49:538-544.
35. Farde L., Wiesel F.A., Nordstrom A.L., Sedvall G. D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology (Berl) 1989, 99(Suppl.):S28-S31.
36. Faridi K., Pawliuk N., King S., Joober R., Malla A.K. Prevalence of psychotic and non-psychotic disorders in relatives of patients with a first episode psychosis. Schizophr Res 2009, 114:57-63.
37. Friedhoff A.J., Bonnet K., Tosengarten H. Reversal of two manifestations of dopamine receptor supersensitivity by administration of L-dopa. Res Commun Chem Pathol Pharmacol 1977, 16:411-423.
38. Fukushiro D.F., Alvarez Jdo N., Tatsu J.A., de Castro J.P., Chinen C.C., Frussa-Filho R. Haloperidol (but not ziprasidone) withdrawal enhances cocaine-induced locomotor activation and conditioned place preference in mice. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:867-872.
39. Fukushiro D.F., Carvalho Rde C., Ricardo V.P., Alvarez Jdo N., Ribeiro L.T., Frussa-Filho R. Haloperidol (but not ziprasidone) withdrawal potentiates sensitization to the hyperlocomotor effect of cocaine in mice. Brain Res Bull 2008, 77:124-128.
40. George T.P., Vessicchio J.C., Termine A., Sahady D.M., Head C.A., Pepper W.T., et al. Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology 2002, 26:75-85.
41. Gershon E.S., DeLisi L.E., Hamovit J., Nurnberger J.I., Maxwell M.E., Schreiber J., et al. A controlled family study of chronic psychoses. Schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 1988, 45:328-336.
42. Gianutsos G., Drawbaugh R.B., Hynes M.D., Lal H. Behavioral evidence for dopaminergic supersensitivity after chronic haloperidol. Life Sci 1974, 14:887-898.
43. Ginovart N., Wilson A.A., Hussey D., Houle S., Kapur S. D2-receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11C]-raclopride PET study in cats. Neuropsychopharmacology 2009, 34:662-671.
44. Halperin R., Guerin J.J., Davis K.L. Chronic administration of three neuroleptics: effects of behavioral supersensitivity mediated by two different brain regions in the rat. Life Sci 1983, 33:585-592.
45. Hambrecht M., Hafner H. Substance abuse and the onset of schizophrenia. Biol Psychiatry 1996, 40:1155-1163.
46. Horger B.A., Shelton K., Schenk S. Preexposure sensitizes rats to the rewarding effects of cocaine. Pharmacol Biochem Behav 1990, 37:707-711.
47. Howell L.L., Byrd L.D. Enhanced sensitivity to the behavioral effects of cocaine after chronic administration of D2-selective dopamine antagonists in the squirrel monkey. J Pharmacol Exp Ther 1992, 262:907-915.
48. Howes O.D., Kambeitz J., Kim E., Stahl D., Slifstein M., Abi-Dargham A., et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 2012, 69:776-786.
49. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr Bull 2009, 35:549-562.
50. Huang N., Ase A.R., Hebert C., van Gelder N.M., Reader T.A. Effects of chronic neuroleptic treatments on dopamine D1 and D2 receptors: homogenate binding and autoradiographic studies. Neurochem Int 1997, 30:277-290.
51. Ichikawa J., Meltzer H.Y. The effect of chronic atypical antipsychotic drugs and haloperidol on amphetamine-induced dopamine release in vivo. Brain Res 1992, 574:98-104.
52. Juckel G., Schlagenhauf F., Koslowski M., Filonov D., Wustenberg T., Villringer A., et al. Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology (Berl) 2006, 187:222-228.
53. Juckel G., Schlagenhauf F., Koslowski M., Wustenberg T., Villringer A., Knutson B., et al. Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage 2006, 29:409-416.
54. Kalivas P.W., Volkow N.D. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 2005, 162:1403-1413.
55. Kapur S., VanderSpek S.C., Brownlee B.A., Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 2003, 305:625-631.
56. Kapur S., Zipursky R., Jones C., Remington G., Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000, 157:514-520.
57. Kavanagh D.J., McGrath J., Saunders J.B., Dore G., Clark D. Substance misuse in patients with schizophrenia: epidemiology and management. Drugs 2002, 62:743-755.
58. Kendler K.S., Gruenberg A.M., Tsuang M.T. Psychiatric illness in first-degree relatives of schizophrenic and surgical control patients. A family study using DSM-III criteria. Arch Gen Psychiatry 1985, 42:770-779.
59. Kerfoot K.E., Rosenheck R.A., Petrakis I.L., Swartz M.S., Keefe R.S., McEvoy J.P., et al. Substance use and schizophrenia: Adverse correlates in the CATIE study sample. Schizophr Res 2011, 132:177-182.
60. Kessler R.M., Whetsell W.O., Ansari M.S., Votaw J.R., de Paulis T., Clanton J.A., et al. Identification of extrastriatal dopamine D2 receptors in post mortem human brain with [125I]epidepride. Brain Res 1993, 609:237-243.
61. Khantzian E.J. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry 1985, 142:1259-1264.
62. Kirsch P., Ronshausen S., Mier D., Gallhofer B. The influence of antipsychotic treatment on brain reward system reactivity in schizophrenia patients. Pharmacopsychiatry 2007, 40:196-198.
63. Kohler C., Radesater A.C. Autoradiographic visualization of dopamine D-2 receptors in the monkey brain using the selective benzamide drug [3H]raclopride. Neurosci Lett 1986, 66:85-90.
64. Kolliakou A., Joseph C., Ismail K., Atakan Z., Murray R.M. Why do patients with psychosis use cannabis and are they ready to change their use?. Int J Dev Neurosci 2011, 29:335-346.
65. Kosten T.A., DeCaprio J.L., Nestler E.J. Long-term haloperidol administration enhances and short-term administration attenuates the behavioral effects of cocaine in a place conditioning procedure. Psychopharmacology (Berl) 1996, 128:304-312.
66. LeDuc P.A., Mittleman G. Schizophrenia and psychostimulant abuse: a review and re-analysis of clinical evidence. Psychopharmacology (Berl) 1995, 121:407-427.
67. Lieberman J.A., Kane J.M., Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl) 1987, 91:415-433.
68. Lorrain D.S., Arnold G.M., Vezina P. Previous exposure to amphetamine increases incentive to obtain the drug: long-lasting effects revealed by the progressive ratio schedule. Behav Brain Res 2000, 107:9-19.
69. Lybrand J., Caroff S. Management of schizophrenia with substance use disorders. Psychiatr Clin North Am 2009, 32:821-833.
70. Marin C., Chase T.N. Dopamine D1 receptor stimulation but not dopamine D2 receptor stimulation attenuates haloperidol-induced behavioral supersensitivity and receptor up-regulation. Eur J Pharmacol 1993, 231:191-196.
71. Martins S.S., Gorelick D.A. Conditional substance abuse and dependence by diagnosis of mood or anxiety disorder or schizophrenia in the U.S. population. Drug Alcohol Depend 2011, 119:28-36.
72. Martres M.P., Bouthenet M.L., Sales N., Sokoloff P., Schwartz J.C. Widespread distribution of brain dopamine receptors evidenced with [125I]iodosulpride, a highly selective ligand. Science 1985, 228:752-755.
73. Meltzer H.Y., Matsubara S., Lee J.C. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989, 25:390-392.
74. Muller P., Seeman P. Dopaminergic supersensitivity after neuroleptics: time-course and specificity. Psychopharmacology (Berl) 1978, 60:1-11.
75. Nielsen M.O., Rostrup E., Wulff S., Bak N., Lublin H., Kapur S., et al. Alterations of the brain reward system in antipsychotic naive schizophrenia patients. Biol Psychiatry 2012, 71:898-905.
76. Noordsy D.L., O'Keefe C., Mueser K.T., Xie H. Six-month outcomes for patients who switched to olanzapine treatment. Psychiatr Serv 2001, 52:501-507.
77. O'Brien C.P., Childress A.R., Ehrman R., Robbins S.J. Conditioning factors in drug abuse: can they explain compulsion?. J Psychopharmacol 1998, 12:15-22.
78. O'Brien C.P., Childress A.R., McLellan A.T., Ehrman R. Classical conditioning in drug-dependent humans. Ann N Y Acad Sci 1992, 654:400-415.
79. O'Dell S.J., La Hoste G.J., Widmark C.B., Shapiro R.M., Potkin S.G., Marshall J.F. Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain. Synapse 1990, 6:146-153.
80. Owen R.R., Fischer E.P., Booth B.M., Cuffel B.J. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatr Serv 1996, 47:853-858.
81. Panlilio L.V., Weiss S.J., Schindler C.W. Cocaine self-administration increased by compounding discriminative stimuli. Psychopharmacology (Berl) 1996, 125:202-208.
82. Pencer A., Addington J. Substance use and cognition in early psychosis. J Psychiatry Neurosci 2003, 28:48-54.
83. Piazza P.V., Deminiere J.M., Le Moal M., Simon H. Factors that predict individual vulnerability to amphetamine self-administration. Science 1989, 245:1511-1513.
84. Potvin S., Blanchet P., Stip E. Substance abuse is associated with increased extrapyramidal symptoms in schizophrenia: a meta-analysis. Schizophr Res 2009, 113:181-188.
85. Potvin S., Pampoulova T., Mancini-Marie A., Lipp O., Bouchard R.H., Stip E. Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder. J Neurol Neurosurg Psychiatry 2006, 77:796-798.
86. Rauser L., Savage J.E., Meltzer H.Y., Roth B.L. Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. J Pharmacol Exp Ther 2001, 299:83-89.
87. Rebec G.V., Peirson E.E., McPherson F.A., Brugge K. Differential sensitivity to amphetamine following long-term treatment with clozapine or haloperidol. Psychopharmacology (Berl) 1982, 77:360-366.
88. Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990, 264:2511-2518.
89. Richfield E.K., Penney J.B., Young A.B. Anatomical and affinity state comparisons between dopamine D1 and D2 receptors in the rat central nervous system. Neuroscience 1989, 30:767-777.
90. Rivest R., Falardeau P., Di Paolo T. Brain dopamine transporter: gender differences and effect of chronic haloperidol. Brain Res 1995, 692:269-272.
91. Roberts D.C., Vickers G. The effect of haloperidol on cocaine self-administration is augmented with repeated administrations. Psychopharmacology (Berl) 1987, 93:526-528.
92. Samaha A.N., Reckless G.E., Seeman P., Diwan M., Nobrega J.N., Kapur S. Less is More: Antipsychotic efficacy is greater with transient rather than continuous drug delivery. Biol Psychiatry 2008, 64:145-152.
93. Samaha A.N., Seeman P., Stewart J., Rajabi H., Kapur S. "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci 2007, 27:2979-2986.
94. Sayers A.C., Burki H.R., Ruch W., Asper H. Neuroleptic-induced hypersensitivity of striatal dopamine receptors in the rat as a model of tardive dyskinesias. Effects of clozapine, haloperidol, loxapine and chlorpromazine. Psychopharmacologia 1975, 41:97-104.
95. Schlagenhauf F., Juckel G., Koslowski M., Kahnt T., Knutson B., Dembler T., et al. Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine. Psychopharmacology (Berl) 2008, 196:673-684.
96. Schneier F.R., Siris S.G. A review of psychoactive substance use and abuse in schizophrenia. Patterns of drug choice. J Nerv Ment Dis 1987, 175:641-652.
97. Schoenmakers T., Wiers R.W., Field M. Effects of a low dose of alcohol on cognitive biases and craving in heavy drinkers. Psychopharmacology (Berl) 2008, 197:169-178.
98. Seeman P., Corbett R., Van Tol H.H. Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology 1997, 16:93-110. [discussion 1-35].
99. Severson J.A., Robinson H.E., Simpson G.M. Neuroleptic-induced striatal dopamine receptor supersensitivity in mice: relationship to dose and drug. Psychopharmacology (Berl) 1984, 84:115-119.
100. Shaham Y., Shalev U., Lu L., De Wit H., Stewart J. The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (Berl) 2003, 168:3-20.
101. Smelson D.A., Losonczy M.F., Davis C.W., Kaune M., Williams J., Ziedonis D. Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Can J Psychiatry 2002, 47:671-675.
102. Smelson D.A., Ziedonis D., Williams J., Losonczy M.F., Steinberg M.L., Kaune M. The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report. J Clin Psychopharmacol 2006, 26:9-12.
103. Smith M.J., Barch D.M., Wolf T.J., Mamah D., Csernansky J.G. Elevated rates of substance use disorders in non-psychotic siblings of individuals with schizophrenia. Schizophr Res 2008, 106:294-299.
104. Smith R.C., Davis J.M. Behavioral supersensitivity to apomorphine and amphetamine after chronic high dose haloperidol treatment. Psychopharmacol Commun 1975, 1:285-293.
105. Smith R.C., Singh A., Infante M., Khandat A., Kloos A. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology 2002, 27:479-497.
106. Stinus L., Nadaud D., Deminiere J.M., Jauregui J., Hand T.T., Le Moal M. Chronic flupentixol treatment potentiates the reinforcing properties of systemic heroin administration. Biol Psychiatry 1989, 26:363-371.
107. Stinus L., Nadaud D., Jauregui J., Kelley A.E. Chronic treatment with five different neuroleptics elicits behavioral supersensitivity to opiate infusion into the nucleus accumbens. Biol Psychiatry 1986, 21:34-48.
108. Strakowski S.M., Tohen M., Flaum M., Amador X. Substance abuse in psychotic disorders: associations with affective syndromes. DSM-IV Field Trial Work Group. Schizophr Res 1994, 14:73-81.
109. Swerdlow N.R. Integrative circuit models and their implications for the pathophysiologies and treatments of the schizophrenias. Curr Top Behav Neurosci 2010, 4:555-583.
110. Tarsy D., Baldessarini R.J. The pathophysiologic basis of tardive dyskinesia. Biol Psychiatry 1977, 12:431-450.
111. Tauscher J., Jones C., Remington G., Zipursky R.B., Kapur S. Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 2002, 7:317-321.
112. Taylor J.R., Horger B.A. Enhanced responding for conditioned reward produced by intra-accumbens amphetamine is potentiated after cocaine sensitization. Psychopharmacology (Berl) 1999, 142:31-40.
113. Thompson J.L., Urban N., Slifstein M., Xu X., Kegeles L.S., Girgis R.R., et al. Striatal dopamine release in schizophrenia comorbid with substance dependence. Mol Psychiatry 2012, [ePub ahead of print].
114. Uslaner J.M., Acerbo M.J., Jones S.A., Robinson T.E. The attribution of incentive salience to a stimulus that signals an intravenous injection of cocaine. Behav Brain Res 2006, 169:320-324.
115. Wadenberg M.L., Soliman A., VanderSpek S.C., Kapur S. Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 2001, 25:633-641.
116. Weinberger D.R., Lipska B.K. Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground. Schizophr Res 1995, 16:87-110.
117. Westermeyer J.J., Schneekloth T.D. Course of substance abuse in patients with and without schizophrenia. Am J Addict 1999, 8:55-64.
118. Wilmot C.A., Szczepanik A.M. Effects of acute and chronic treatments with clozapine and haloperidol on serotonin (5-HT2) and dopamine (D2) receptors in the rat brain. Brain Res 1989, 487:288-298.
119. Winterer G. Why do patients with schizophrenia smoke?. Curr Opin Psychiatry 2010, 23:112-119.
120. Wolfling K., Flor H., Grusser S.M. Psychophysiological responses to drug-associated stimuli in chronic heavy cannabis use. Eur J Neurosci 2008, 27:976-983.
121. Zhang J.Y., Kowal D.M., Nawoschik S.P., Lou Z., Dunlop J. Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochem Pharmacol 2006, 71:521-529.
122. Ziedonis D., Hitsman B., Beckham J.C., Zvolensky M., Adler L.E., Audrain-McGovern J., et al. Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. Nicotine Tob Res 2008, 10:1691-1715.